The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: Validation in the victor trial

Annals of Oncology

Volumn 24, Issue 1, 2013, Pages 179-185

  Huijbers, A ^a   Tollenaar, R A E M ^a   Pelt, G W V ^a   Zeestraten, E C M ^a   Dutton, S ^b   McConkey, C C ^d   Domingo, E ^e   Smit, V T H B M ^a   Midgley, R ^c   Warren, B F ^f   Johnstone, E C ^c   Kerr, D J ^c   Mesker, W E ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF WARWICK   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

ASCO; Colon cancer; Pathology; Prognostic; Stroma; VICTOR

Indexed keywords

PLACEBO; ROFECOXIB;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; COLON CANCER; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; STROMA; SURVIVAL TIME; TUMOR STROMA; VALIDATION PROCESS;

EID: 84871592878     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds246     Document Type: Article

References (21)

1. Gray R, Barnwell J, McConkey C et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007; 370: 2020-2029.
2. QUASAR Collaborative Group. Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. Lancet 2000; 355: 1588-1596.
3. Mesker WE, Liefers GJ, Junggeburt JM et al. Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients. Cell Oncol 2009; 31: 169-178.
4. Mesker WE, Junggeburt JM, Szuhai K et al. The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage. Cell Oncol 2007; 29: 387-398.
5. West NP, Dattani M, McShane P et al. The proportion of tumour cells is an independent predictor for survival in colorectal cancer patients. Br J Cancer 2010; 102: 1519-1523.
6. Courrech Staal EF, Wouters MW, van Sandick JW et al. The stromal part of adenocarcinomas of the oesophagus: does it conceal targets for therapy? Eur J Cancer 2010; 46: 720-728.
7. de Kruijf EM, van Nes JG, van de Velde CJ et al. Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients. Breast Cancer Res Treat 2010; 125: 687-696.
8. Midgley RS, McConkey CC, Johnstone EC et al. Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial. J Clin Oncol 2010; 28: 4575-4580.
9. Pendlebury S, Duchesne F, Reed KA et al. A trial of adjuvant therapy in colorectal cancer: the VICTOR trial. Clin Colorectal Cancer 2003; 3: 58-60.
10. Baron JA, Sandler RS, Bresalier RS et al. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet 2008; 372: 1756-1764.
11. Baron JA, Sandler RS, Bresalier RS et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006; 131: 1674-1682.
12. Bresalier RS, Sandler RS, Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-1102.
13. Kerr DJ, Dunn JA, Langman MJ et al. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N Engl J Med 2007; 357: 360-369.
14. Boland CR, Thibodeau SN, Hamilton SR et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58: 5248-5257.
15. Punt CJ, Buyse M, Kohne CH et al. Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst 2007; 99: 998-1003.
16. Sobin LH, Fleming ID. TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997; 80: 1803-1804.
17. Ribic CM, Sargent DJ, Moore MJ et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349: 247-257.
18. Kim ST, Lee J, Park SH et al. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Cancer Chemother Pharmacol 2010; 66: 659-667.
19. de Vos tot Nederveen Cappel WH, Meulenbeld HJ, Kleibeuker JH et al. Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer. Int J Cancer 2004; 109: 468-471.
20. Sargent DJ, Marsoni S, Monges G et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010; 28: 3219-3226.
21. Bertagnolli MM, Niedzwiecki D, Compton CC et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol 2009; 27: 1814-1821.